Related Experiment Video
Updated: May 7, 2026
08:53
A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo
Published on: January 10, 2025
Does erythropoietin always win?
V Cernaro, A Lacquaniti, A Buemi
1Via Salita Villa Contino, 30 98100 Messina, Italy. buemim@unime.it.
Current Medicinal Chemistry
|September 25, 2013
Summary
Erythropoiesis-stimulating agents (ESAs) treat anemia in kidney disease but carry risks. Guidelines now balance ESA benefits against potential cardio-cerebrovascular complications and cancer progression concerns.
Area of Science:
- Nephrology
- Hematology
- Oncology
Background:
- Recombinant human erythropoietin (EPO) revolutionized anemia treatment in chronic kidney disease (CKD).
- High-dose erythropoiesis-stimulating agent (ESA) use is linked to severe cardiovascular and cerebrovascular events, as seen in doping cases.
- EPO's angiogenic and growth factor properties raise concerns about cancer progression.
Purpose of the Study:
- To review current guidelines for managing anemia in nephropathic patients.
- To analyze the risk-benefit balance of ESA therapy.
- To identify potential risks associated with targeting very low hemoglobin levels.
Main Methods:
- Literature review of recent guidelines on anemia management in CKD.
- Analysis of safety data regarding ESA use.
- Evaluation of EPO's role in cancer progression.
Main Results:
- Ongoing debate exists regarding optimal hemoglobin targets for ESA therapy.
- Potential risks include cardiovascular/cerebrovascular complications and favoring neoplastic disease progression.
- Aggressively low hemoglobin targets may also pose risks.
Conclusions:
- Careful consideration of ESA risks and benefits is crucial in CKD anemia management.
- Optimal hemoglobin levels remain a subject of clinical discussion.
- Further research is needed to refine ESA treatment protocols, especially in cancer patients.
Related Concept Videos
01:14Erythropoiesis
Red blood cells (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...
01:14Erythropoiesis
Red blood cells (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...
01:24Factors Affecting Erythropoiesis
The cardiovascular system regulates the number of erythrocytes in the bloodstream to ensure optimal oxygen transport. It also prevents over-proliferation of these cells, which helps to maintain blood viscosity and flow rate.
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
01:28Role of Hematopoietic Growth Factors
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
01:17Hormonal Regulation of Blood Pressure
Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
01:22Lifecycle of Erythrocytes
Erythrocytes, also known as red blood cells, constantly move through blood capillaries. As a result, they damage their plasma membrane due to the continuous friction. Typically, after 100 to 120 days, erythrocytes become rigid and fragile as they wear out. As they pass through small vessels in the spleen and liver, they can get trapped and break apart into fragments.
The resident phagocytic macrophages deal with these damaged cells by engulfing them and separating their globin and heme groups.
The resident phagocytic macrophages deal with these damaged cells by engulfing them and separating their globin and heme groups.